Q2 2025 Perimeter Medical Imaging AI Inc Earnings Call Transcript
Key Points
- Perimeter Medical Imaging AI Inc (PYNKF) reported a 105% increase in revenue over Q2 2024, indicating strong financial growth.
- The company achieved a gross margin of 70% for the second quarter of 2025, maintaining stability from the previous year.
- Utilization rates for the S-Series OCT device increased by 93% year over year and 35% sequentially quarter over quarter, demonstrating growing adoption.
- The company surpassed a significant milestone with over 3,000 patients imaged using their technology, highlighting its impact in clinical settings.
- Perimeter Medical Imaging AI Inc (PYNKF) is preparing for an aggressive rollout of the B-Series device pending FDA approval, which could significantly expand their market presence.
- The company reported a net loss of $3.9 million for the second quarter of 2025, an increase from the $3.2 million loss in the same period in 2024.
- Operating expenses were $4.3 million, although this was a 22% improvement from the previous year, it still represents a significant cost.
- Cash and cash equivalents were approximately $1.4 million as of June 30, 2025, indicating limited liquidity.
- The company is dependent on FDA approval for the B-Series device, which introduces uncertainty regarding the timing of its market launch.
- Perimeter Medical Imaging AI Inc (PYNKF) faces challenges in scaling its commercial team to meet growing demand, which could limit sales growth.
Good afternoon ladies and gentlemen, and welcome to the Perimeter Medical second quarter 2025 conference call. (Operator Instructions) This call is being recorded on Tuesday, August 26, 2025.
I would now like to turn the conference over to Stephen Kilmer, Investor Relations. Please go ahead.
Thank you. Good afternoon, everyone. Let me start by pointing out that this conference call will include forward-looking statements within the meaning of applicable securities laws. These may include statements regarding the future financial position, business strategy and strategic goals, commercial activities and timing competitive conditions, research and development activities, projected costs and capital expenditures research and clinical testing outcomes, the potential benefits of our products, including Perimeter S-Series OCT, Perimeter B-Series OCT and Perimeter Image Assist.
Perimeter's ability to broaden its user base and the expected approval of this proprietary AI,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
